Bluebird Bio secures up to $175M in debt financing with Hercules Capital to extend its cash runway beyond the next 24 months.

Mar 18, 2024•over 1 year ago

Amount Raised

$175 Million

SomervilleHealth CareBiotechnology

Investors

Hercules Capital

Description

Bluebird Bio has secured up to $175 million in debt financing with Hercules Capital in a five-year term loan facility, which provides for the funds in separate tranches. The firm anticipates that the funding will extend its cash runway beyond the next 24 months.

Company Information

Company

bluebird bio

Location

455 Grand Union Boulevard

Somerville, Pennsylvania, United States

About

bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care.

Related People

5 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends